Trial Profile
An open-label, single center study to evaluate the pharmacokinetics of single dose Axitinib in fasted state healthy male volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Cancer; Renal cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 05 Dec 2015 New trial record